RIDDLE&CODE-GMBH
23.8.2022 10:17:11 CEST | Business Wire | Press release
Riddle&Code GmbH is pleased to announce John Calian as the new CEO of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005122/en/
"I am grateful to have been selected as Riddle&Code's next CEO. We are an organisation led by a purpose – to onboard industrial machines to Web3. It is a privilege to lead a team dedicated to machine-driven token economies, enabling sustainable, green, resilient energy systems," said Calian. "That is the mission of our company. I will do my best to serve the team and our customers by enabling our leaders and people to do their best work."
This decision comes at a momentous time, as Riddle&Code evolves into a product-led service company specialising in Web3 infrastructure and establishing the unique RDDL Network blockchain, which provides the cornerstones for decentralised, secure, and trusted machine economies. Riddle&Code is preparing to be a key contributor to this network and aims to provide the best products, services, and solutions to make this vision flourish.
Working with enterprise partners such as Wien Energie, Daimler Mobility, Evonik, Litebit, and Telekom Innovation Laboratories (T-Labs), Riddle&Code has built an extensive portfolio of blockchain-powered software and hardware products across key industry segments, highlighted by renewable energy producers, electric vehicle manufacturers and large scale energy storage systems providers.
"We are at a natural turning point for the company, and John brings the leadership and expertise needed for Riddle&Code to enter this next phase. Our new purpose is to share our established knowledge and onboard as many industries as possible to Web3 to shape the future of interconnecting token economies with the RDDL Network. This goes way beyond the wildest ambitions of current token projects and energy tech companies." ~ Tom Fürstner, Founder and CTO of Riddle&Code.
The landscape for decentralised infrastructure is rapidly changing, and there has been an increase in demand for blockchain-based software systems due to the ongoing shift towards Web3. This new era requires industries to set up new operating and business models, combining old strengths with a new way of thinking.
Riddle&Code is now focused on being a key player in onboarding industries to Web3 and will provide specific products and services. Co-Founder and outgoing CEO Alexander Koppel will continue as Advisor to the CEO in the future and further support the company's mission. This announcement is the logical next step in the further evolution and continued progress of Riddle&Code and its subsidiary companies.
About Riddle&Code
Riddle&Code is a product-led services company specialising in onboarding industries to Web3. The company is the main driver for a world of interconnected token economies by enabling sustainable, green, and resilient machine industries. Riddle&Code offers various solutions to tailor industry-specific hardware wallets and an application suite to build on decentralised blockchains, mainly contributing to the RDDL Network blockchain protocol.
More information: www.riddleandcode.com
About the RDDL Network
The RDDL Network is a decentralised, industrial machine-powered blockchain protocol that uses a unique Proof-of Productivity (PoP) consensus mechanism that proves identity, data accuracy, and usage for all types of machines. It addresses infrastructure and standards as a whole and is designed to shape the future of interconnected token economies for the fourth industrial revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005122/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom